Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY | Market Cap | 4.61T +63.4% |
| Revenue (ttm) | 2.27T +16.9% |
| Net Income | 364.94B +347.4% |
| EPS | 203.04 +347.3% |
| Shares Out | 1.79B |
| PE Ratio | 12.66 |
| Forward PE | 11.94 |
| Dividend | 80.00 (3.11%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 6,563,100 |
| Open | 2,521.50 |
| Previous Close | 2,513.00 |
| Day's Range | 2,513.50 - 2,594.00 |
| 52-Week Range | 1,557.50 - 2,717.00 |
| Beta | 0.05 |
| Analysts | Buy |
| Price Target | 2,536.43 (-1.34%) |
| Earnings Date | Nov 4, 2026 |
About Astellas Pharma
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degen... [Read more]
Financial Performance
In fiscal year 2026, Astellas Pharma's revenue was 2.14 trillion, an increase of 11.87% compared to the previous year's 1.91 trillion. Earnings were 291.54 billion, an increase of 474.49%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for 4503 stock is "Buy." The 12-month stock price target is ¥2,536, which is a decrease of -1.34% from the latest price.
News
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology
TOKYO and MELBOURNE, Australia, Oct. 27, 2026 /PRNewswire/ -- Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced tha...
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigationa...
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
– Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") to...
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Astellas Pharma Earnings Call Transcript: Q1 2027
Revenue and profits reached record highs, driven by strong growth in strategic brands and disciplined cost management. Pipeline advanced with key approvals and rapid trial enrollment, while cost optimization supported high margins. Growth momentum is expected to continue.
Astellas Pharma Quarterly report: Q1 2027
Astellas Pharma has published its Q1 2027 quarterly earnings report on August 5, 2026.
Astellas Pharma Slides: Q1 2027
Astellas Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
Astellas Pharma Transcript: Jefferies Global Healthcare Conference 2026
A new five-year plan targets sustainable, pipeline-led growth, doubling strategic brand sales, and record revenues by the mid-2030s. Major R&D investments focus on oncology, including KRAS and Claudin 18.2 programs, with disciplined cash allocation and cost optimization supporting profitability.
Astellas Pharma Slides: FY 2026
Astellas Pharma has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s - - CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led g...
Astellas Pharma Slides: Investor presentation
Astellas Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
Oral presentation highlights early progress of investigational ASP7317 in the treatment of advanced geographic atrophy Encore oral presentation features long-term outcomes for IZERVAY ® (avacincaptad ...
Astellas Pharma Earnings Call Transcript: Q4 2026
Record-high revenue and profit were achieved, driven by strong growth in strategic brands and effective cost optimization. FY 2026 guidance projects continued double-digit profit growth, increased R&D investment, and a stable dividend policy, while monitoring risks from U.S. pricing and patent expirations.
Astellas Pharma Slides: Q4 2026
Astellas Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 27, 2026.
Astellas Pharma Quarterly report: Q4 2026
Astellas Pharma has published its Q4 2026 quarterly earnings report on April 27, 2026.
Astellas Pharma Transcript: R&D Day 2026
Multiple flagship assets achieved proof of concept, with phase III trials underway in key indications. Strategic focus, disciplined portfolio management, and digital transformation are driving pipeline progress and operational efficiency, supporting long-term growth and financial targets.
Astellas Pharma Slides: FY 2026
Astellas Pharma has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 30, 2026.
Astellas Pharma Slides: Investor presentation
Astellas Pharma has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
What's Happening With VIR Stock?
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P...
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn...
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product ...
Astellas Pharma Earnings Call Transcript: Q3 2026
Q3 FY2025 saw double-digit revenue and profit growth, driven by strategic brands and cost optimization. Full-year forecasts were revised upward, with strong sales from PADCEV, IZERVAY, VYLOY, VEOZAH, and XTANDI, and significant pipeline progress supporting future growth.
Astellas Pharma Quarterly report: Q3 2026
Astellas Pharma has published its Q3 2026 quarterly earnings report on February 4, 2026.
Astellas Pharma Slides: Q3 2026
Astellas Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.